CERo Therapeutics Holdings, Inc. (CERO)
OTCMKTS · Delayed Price · Currency is USD
0.0270
+0.000405 (1.52%)
At close: May 18, 2026

CERO Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cost of Revenue
0.610.61----
Gross Profit
-0.61-0.61----
Selling, General & Admin
10.259.7910.733.952.840.43
Research & Development
8.118.685.473.72--
Other Operating Expenses
----0.060.14
Operating Expenses
19.0719.3316.27.682.910.57
Operating Income
-19.67-19.93-16.2-7.68-2.91-0.57
Interest & Investment Income
0.010.010.030.142.84-
Other Non Operating Income (Expenses)
-0.8804.530.24--
EBT Excluding Unusual Items
-20.7-19.92-11.64-7.3-0.07-0.57
Gain (Loss) on Sale of Investments
------0
Other Unusual Items
--3.340.01--
Pretax Income
-20.7-19.92-8.3-7.29-0.07-0.57
Income Tax Expense
----0.6-0.03
Net Income
-20.7-19.92-8.3-7.29-0.67-0.54
Preferred Dividends & Other Adjustments
75.2675.612.78--36.16
Net Income to Common
-95.96-95.53-11.09-7.29-0.67-36.71
Shares Outstanding (Basic)
1140-0-
Shares Outstanding (Diluted)
1140-0-
Shares Change (YoY)
19215.02%16477.89%----
EPS (Basic)
-8.44-22.58-434.62--59.38-
EPS (Diluted)
-8.44-22.58-434.62--59.38-
EBITDA
-19.4-19.65-15.76-7.21--
D&A For EBITDA
0.270.280.440.46--
EBIT
-19.67-19.93-16.2-7.68-2.91-0.57
Source: S&P Global Market Intelligence. Standard template. Financial Sources.